State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

State Street Corp boosted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,496,739 shares of the company's stock after purchasing an additional 512,682 shares during the quarter. State Street Corp owned about 1.64% of Aquestive Therapeutics worth $7,454,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in AQST. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the second quarter worth approximately $27,000. nVerses Capital LLC acquired a new position in Aquestive Therapeutics in the third quarter valued at about $28,000. The Manufacturers Life Insurance Company bought a new stake in Aquestive Therapeutics during the second quarter worth about $76,000. Financial Advocates Investment Management increased its holdings in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company's stock valued at $88,000 after buying an additional 14,000 shares during the period. Finally, Harvey Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $88,000. Institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Stock Performance

Shares of AQST stock traded down $0.14 on Friday, hitting $3.52. The company had a trading volume of 1,159,568 shares, compared to its average volume of 1,725,974. Aquestive Therapeutics, Inc. has a twelve month low of $1.95 and a twelve month high of $6.23. The firm has a market cap of $320.95 million, a P/E ratio of -7.82 and a beta of 2.62. The stock's 50-day moving average is $4.58 and its two-hundred day moving average is $4.09.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analysts' expectations of $12.69 million. During the same period last year, the firm posted ($0.03) EPS. Equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AQST. Leerink Partners raised their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $17.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $11.00.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.